key: cord-0702265-h2ekt8qy
authors: van de Munckhof, Anita; Krzywicka, Katarzyna; Aguiar de Sousa, Diana; Sánchez van Kammen, Mayte; Heldner, Mirjam R.; Jood, Katarina; Lindgren, Erik; Tatlisumak, Turgut; Putaala, Jukka; Kremer Hovinga, Johanna A.; Middeldorp, Saskia; Levi, Marcel; Arnold, Marcel; Ferro, José M.; Coutinho, Jonathan M.
title: Declining mortality of cerebral venous sinus thrombosis with thrombocytopenia after SARS‐CoV‐2 vaccination
date: 2021-10-01
journal: Eur J Neurol
DOI: 10.1111/ene.15113
sha: 583442ed50ab8e5a75f451e01f2e4aa2403498ba
doc_id: 702265
cord_uid: h2ekt8qy

BACKGROUND AND PURPOSE: High mortality rates have been reported in patients with cerebral venous sinus thrombosis (CVST) due to vaccine‐induced immune thrombotic thrombocytopenia (VITT) after vaccination with adenoviral vector SARS‐CoV‐2 vaccines. The aim of this study was to evaluate whether the mortality of patients with CVST‐VITT has decreased over time. METHODS: The EudraVigilance database of the European Medicines Agency was used to identify cases of CVST with concomitant thrombocytopenia occurring within 28 days of SARS‐CoV‐2 vaccination. Vaccines were grouped based on vaccine type (adenoviral or mRNA). Cases with CVST onset until 28 March were compared to cases after 28 March 2021, which was the day when the first scientific paper on VITT was published. RESULTS: In total, 270 cases of CVST with thrombocytopenia were identified, of which 266 (99%) occurred after adenoviral vector SARS‐CoV‐2 vaccination (ChAdOx1 nCoV‐19, n = 243; Ad26.COV2.S, n = 23). The reported mortality amongst adenoviral cases with onset up to 28 March 2021 was 47/99 (47%, 95% confidence interval 37%–58%) compared to 36/167 (22%, 95% confidence interval 16%–29%) in cases with onset after 28 March (p < 0.001). None of the four cases of CVST with thrombocytopenia occurring after mRNA vaccination died. CONCLUSION: The reported mortality of CVST with thrombocytopenia after vaccination with adenoviral vector‐based SARS‐CoV‐2 vaccines has significantly decreased over time, which may indicate a beneficial effect of earlier recognition and/or improved treatment on outcome after VITT.

. Early reported mortality rates amongst patients with VITT, especially those with CVST, were high, ranging between 30% and 60% [1] [2] [3] [4] . After the discovery that the underlying pathophysiology of anti-platelet factor 4 antibody-induced platelet activation resembled an autoimmune variant of heparin induced thrombocytopenia, specific treatment recommendations different from standard CVST care were proposed, based on the following three pillars: (i) use of nonheparin based anticoagulants, (ii) use of immunomodulation, with intravenous immunoglobulin as first-line treatment and (iii) avoidance of platelet transfusion [1, 7] . Now that VITT is a recognized side effect and treatment recommendations are in place which are widely endorsed by international organizations [8, 9] , the question arises whether the outcome of patients with CVST-VITT has improved over time. In an attempt to answer this question, acute mortality rates from the EudraVigilance database of the European Medicines Agency (EMA) were compared in two different time periods.

This is an extension of a previously published study which also used EudraVigilance data and where the methods are described in more detail [4] . Briefly, EudraVigilance is a passive pharmacovigilance system hosted and maintained by EMA in which suspected adverse drug reactions (ADRs) are collected from countries inside and outside the European Economic Area (EEA). Marketing authorization holders and national competent authorities are obliged to report any suspected ADRs occurring within the EEA as well as any suspected serious ADRs occurring within and outside the EEA [10] .

The authors were granted level 2A access to the Medical Dictionary for Regulatory Activities High Level Group Term (MedDRA HLGT, version 24.0) 'Central nervous system vascular disorders' [11] . For the current study, data on all suspected adverse events reported to (Table S1 ).

Cases marked as 'suspected CVST' after screening were adjudicated by a senior vascular neurologist (JMC). Cases were marked as having concomitant thrombocytopenia if a PT related to thrombocytopenia was reported (Table S1 ), or if they had a reported platelet count of <150 × 10 9 /L (Table S2) . For the analysis, the adenoviral vectorbased vaccines were grouped together, as were the mRNA vaccines.

Because of a potential delay between CVST onset and death, all cases with CVST onset after 30 May 2021 were excluded from the analysis.

As a baseline characteristic, the adenoviral vector vaccine group was screened for adverse reactions coded with PTs related to intracranial haemorrhage (Table S1 ). Only intracranial haemorrhages with a reported onset date prior to or equal to the CVST onset date were included. In addition, the adenoviral vector vaccine group was screened for cases with any confirmed COVID-19 infection (Tables S1 and S2 ).

To evaluate a shift in mortality over time, cases with CVST onset up to and including 28 March were compared to those with onset after 28 March 2021. This cut-off date was selected because on 28 March (p < 0.001). None of the four cases of CVST with thrombocytopenia occurring after mRNA vaccination died.

The reported mortality of CVST with thrombocytopenia after vaccination with adenoviral vector-based SARS-CoV-2 vaccines has significantly decreased over time, which may indicate a beneficial effect of earlier recognition and/or improved treatment on outcome after VITT.

cerebral venous sinus thrombosis, COVID-19 vaccines, mortality, sinus thrombosis, intracranial, thrombocytopenia that day the first paper on VITT, which included treatment recommendations, was published on a preprint server, receiving worldwide attention both amongst physicians and in the media [1, 13] .

Medians and interquartile ranges were calculated for continuous variables, and counts and percentages for categorical variables.

Ninety-five percent confidence intervals (95% CI) for mortality rates were calculated using the Clopper-Pearson exact method.

A chi-square test was performed to compare the mortality of CVST between the two time periods. A sensitivity analysis was performed restricted to subjects within the EEA and UK because of a potential reporting bias by non-EEA countries, which initiated Group characteristics are shown in Table 1 In the sensitivity analysis using only cases from the EEA and UK, mortality rates were comparable to the mortality rates when including all countries with 45/95 (47%, 95% CI 37%-58%) in cases with onset until 28 March compared to 34/147 (23%, 95% CI 17%-31%) in cases with CVST onset after 28 March.

It was found that the reported mortality of CVST with thrombocytopenia after vaccination with adenoviral vector SARS-CoV-2 vaccines has fallen substantially, from 47% to 22% in cases with symptom onset before and after 28 March 2021, respectively. This decrease in mortality could be the result of earlier diagnosis and/or improved treatment, but this cannot be ascertained with certainty from the EudraVigilance data. Although limited information on treatment effects in CVST-VITT is available [8] , intravenous immunoglobulins have been found to raise platelet counts and decrease hypercoagu- For instance, most countries prioritized vaccination for those most at risk of severe disease [14] , such as older people and people with underlying health conditions, and these people could have a higher risk of death after VITT. Thirdly, mortality can theoretically have been higher in the earlier cases because of a longer follow-up time. Unfortunately, date of death is not systematically recorded in EudraVigilance. However, since the mortality rate in the earlier cases is similar to our previous analysis which contained EudraVigilance data until 8 April 2021 (mortality rate 49%) [4] , the longer follow-up duration is an unlikely explanation for the observed difference in mortality.

As previously reported [4] , the most important limitation of the study is the quality and completeness of the EudraVigilance database. Because EudraVigilance is a passive pharmacovigilance system, a risk of underreporting is present, especially for less severe cases. Data were not centrally validated, and thus the accuracy and completeness of the reported information are unknown. Because marketing authorization holders and national competent authorities can only report ADRs that they are aware of, a risk of selective reporting remains present. In addition, some patients with CVST-VITT prior to 28 March 2021 probably remained undiagnosed, because VITT was an unknown condition at that time. Acute death caused by CVST-VITT could have been misclassified, potentially resulting in an underestimation of the reported mortality rate before 28 March.

The numbers of CVST cases after Ad26.COV2.S vaccination were limited, making it difficult to draw any conclusions on trends in mortality for the adenoviral vector vaccines separately.

In summary, the reported mortality of CVST with thrombocytopenia after vaccination with adenoviral vector-based SARS-CoV-2 vaccines decreased over time, which could indicate a beneficial [4, 15] .

The authors greatly acknowledge the support of EMA staff with the analysis and interpretation of the data. 

Data curation (equal); formal analysis (equal); investigation (equal)

Katarzyna Krzywicka: Data curation (equal); investigation (equal); project administration (equal); validation (equal); visualization (equal); writing-original draft (equal); writing-review and editing (equal)

Jukka Putaala: Investigation (equal); writing-review and editing (equal)

Marcel Arnold: Conceptualization (equal); investigation (equal); writing-review and editing (equal)

writing-original draft (equal); writing-review and editing (equal)

Conceptualization (equal); investigation (equal); resources (equal); supervision (equal); writing-original draft (equal); writing-review and editing (equal)

Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination

Thrombosis and thrombocytopenia after ChAdOx1 nCoV-19 vaccination

Pathologic antibodies to platelet factor 4 after ChAdOx1 nCoV-19 vaccination

Post-SARS-CoV-2-vaccination cerebral venous sinus thrombosis: an analysis of cases notified to the European Medicines Agency

US case reports of cerebral venous sinus thrombosis with thrombocytopenia after Ad26.COV2.S vaccination

SARS-CoV-2 vaccine-induced immune thrombotic thrombocytopenia

Autoimmune heparin-induced thrombocytopenia

American Heart Association/American Stroke Association Stroke Council Leadership. Diagnosis and management of cerebral venous sinus thrombosis with vaccine-induced immune thrombotic thrombocytopenia

The International Society on Thrombosis and Haemostasis. ISTH Interim Guidance for the Diagnosis and Treatment on Vaccine-Induced Immune Thrombotic Thrombocytopenia

6/The-ISTH-Relea ses-Inter im-Guida nce-on

EudraVigilance: Electronic reporting

Access to EudraVigilance Data

Frequency of thrombocytopenia and platelet factor 4/heparin antibodies in patients with cerebral venous sinus thrombosis prior to the COVID-19 pandemic

Here's What to Know about the Risk of Blood Clots and the AstraZeneca Vaccine

European Centre for Disease Prevention and Control. COVID-19 Vaccination-Prioritisation of Target Groups for Vaccination

Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT)

The corresponding author affirms that this research complies with internationally accepted standards for research practice and reporting. This analysis is based on data collected for pharmacovigilance purposes. No patients were directly recruited or actively involved.Since no human participants were involved, ethical approval or patient informed consent was not required.

De-identified participant data from the EudraVigilance database are not publicly available but may be obtained from the European Medicines Agency upon official request [11] .